Special Issue "Antifungal Agents Recently Approved or Under Development"
A special issue of Journal of Fungi (ISSN 2309-608X).
Deadline for manuscript submissions: closed (30 September 2020).
Interests: antifungal susceptibility testing and development of ECVs for fungal species; antifungal resistance; medical mycology; epidemiology
Interests: human pathogenic fungi; antifungals; mycoses; aspergillus; in vitro susceptibility testing; antifungal resistance; animal models
Special Issues and Collections in MDPI journals
Special Issue in Journal of Fungi: Antifungal Combinations in Fungal Infections
Although several antifungal agents are available for the treatment of invasive fungal infections, some factors demand the development of other agents with different mechanisms of activity against resistant emerging pathogens, cryptic species, and the continued incidence of antifungal resistance among both Candida and Aspergillus. Therefore, some agents have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) or are in clinical development, such as: isavuconazole (aspergillosis and mucormycosis and/or when amphotericin B is inappropriate), rezafungin (CD101)) and ibrexafungerp (SCY-078), glucan synthase inhibitors (orphan drug for candidemia and invasive candidiasis and fluconazole failure treatment, respectively), encochleated formulation of amphotericin B (MAT2203) for cryptococcosis, and olorofim (F901318), a member of a new class of antifungal agents, the orotomides (invasive fungal infections lacking treatment options). Several more are in earlier developmental stages: manogepix (Amplyx, E1210) (candidemia and IFI), VT-1598 (preclinical development for coccidioidomycosis), and nikkomycin Z, a chitin synthase inhibitor (potential use for uncomplicated coccidioides pneumonia).
A literature review would explore their molecular mechanisms of action and resistance, availability in vitro, PK/PD, safety and efficacy information data from ongoing clinical trials, and the specific approved designation for the treatment of invasive fungal infections.
Dr. Ana V. Espinel-Ingroff
Dr. Eric Dannaoui
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Beta-1-3-glucane synthase inhibitors
- chitin syntase inhibitors
- GPI inhibitors
- Antifungal resistance